Washington University Medical Center

St Louis, Missouri 65105

7 studies enrolling now · 68 studies all time

What they study most

ALK-Positive Lung Cancer, ALK-positive NSCLC, ALK-positive Non-small Cell Lung Cancer, ALS, Acid Maltase Deficiency Disease, Acoustic Neuroma, Adipocytic Neoplasm, Adult Acute Lymphoid Leukemia, Adult Acute Myeloid Leukemia, Amyotrophic Lateral Sclerosis, Anaplastic Astrocytoma, Angiomatoid Fibrous Histiocytoma

Studies at this site

• NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) — Recruiting now
• A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC — Recruiting now
• Horizon Two: HR NDMM (MMRC-100) — Recruiting now
• TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention — Recruiting now
• CoMind Early Feasibility Study — Recruiting now
• Intermuscular Coherence as a Biomarker for ALS — Recruiting now
• Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy — Recruiting now
• A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions — Running, not enrolling
• A Study of LY2784544 in Participants With Myeloproliferative Neoplasms — Running, not enrolling
• Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy — Completed
• Open Label Extension Study of AMX0035 in Patients With ALS — Completed
• Safety, Testing/Transmission, and Outcomes in Pregnancies With COVID-19 — Completed
• AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) — Completed
• PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban — Stopped early
• mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM) — Withdrawn before enrolling
• Closure Of Patent Ductus Arteriosus With the AMPLATZER Duct Occluder the AMPLATZER® Duct Occluder — Completed
• Safety and Biodistribution of Technetium Tc 99m EC20 in Normal Volunteers and Ovarian Cancer Patients — Completed
• Treatments Against RA and Effect on FDG-PET/CT — Completed
• Open-label Leucovorin Pharmacokinetic Study in Patients Receiving High Dose Methotrexate With or Without Voraxaze — Completed
• Clinical Evaluation of a Cochlear Implant Sound Processor — Completed
• Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia — Completed
• A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies — Completed
• Concentration and Activity of Lapatinib in Vestibular Schwannomas — Completed
• A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain — Completed
• Study of Ambrisentan in Participants With Pulmonary Hypertension — Completed
• ClearVoice Sound-processing Strategy for AB HiRes 120 Cochlear Implant Users — Completed
• Bronchial Thermoplasty 10+ Year Study — Completed
• All in One Study: A Prospective Trial of Electromagnetic Navigation for Biopsy of Pulmonary Nodules — Completed
• A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer — Completed
• A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma — Completed
• A Study of Tadalafil for Duchenne Muscular Dystrophy — Stopped early
• Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency — Completed
• A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants — Completed
• Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) — Stopped early
• Omega-3 for Depression and Other Cardiac Risk Factors - 2 — Completed
• Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia — Stopped early
• A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma — Completed
• Closure of Muscular Ventricular Septal Defects With The AMPLATZER™ Muscular VSD Occluder — Completed
• Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma — Completed
• Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) — Completed
• Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma — Completed
• Closure of Perimembranous Ventricular Septal Defects With The AMPLATZER® Membranous VSD OCCLUDER — Completed
• Collaborative Tinnitus Research at Washington University — Completed
• Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors — Completed
• Cleancision IntRaoperative Contamination prEvention Study — Completed
• Effect of Red Blood Cell Transfusion on Brain Metabolism in Patients With Subarachnoid Hemorrhage — Completed
• Safety and Hemostatic Efficacy of Fibrin Sealant Vapor Heated, Solvent/Detergent Treated (FS VH S/D) Compared With Currently Licensed TISSEEL VH Fibrin Sealant in Subjects Undergoing Cardiac Surgery — Completed
• Live Lung Donor Retrospective Study — Completed
• A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus — Withdrawn before enrolling
• Screening Protocol to Evaluate Acid Alpha-Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease — Completed